In 2025, Indian pharma reached a turning point, thanks to important reforms and the introduction of the Research Development Incentive (RDI) Scheme. Experts see innovation and improved access as vital for growth in 2026.
The Indian pharmaceutical industry has come a long way. Over the past 25 years, it grew from a modest $3 billion to a whopping $60 billion. Looking ahead, the next 25 years will focus on innovation, quality, and accessibility for patients.
Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, emphasized that 2025 marked a key moment. Major GST reforms improved affordability and access to medicines. He pointed out that new quality guidelines and regulatory reforms align India with global standards. These changes aim to make the industry easier to navigate for future growth.
Jain also praised the rollout of the PRIP scheme, which received enthusiasm from the industry, showcasing the sector’s commitment to progress.
Leading companies are now aiming for higher-value products, forming licensing deals, and getting approvals for next-gen drugs. The RDI Scheme is timely, especially as more than $300 billion worth of drugs are losing patent protection soon.
Ameera Shah, President of NATHEALTH, observed significant shifts in healthcare in 2025. The focus moved from merely treating illness to promoting wellness. Digital tools transitioned from the sidelines to playing central roles, revolutionizing clinical workflows and decision-making.
Healthcare investments surged, with hospitals and tech firms enhancing their data infrastructure and automation. These are not just future goals; they are essential for effective healthcare delivery.
Experts predict that 2026 will mark a crucial decade for healthcare. Boosting innovation and widening access will be key for India to establish itself as a global leader by 2047.
“The next five years will be vital,” Jain noted. “Turning policies into real benefits is essential for our ambition to grow into a $450-500 billion industry.”
As major therapies go off patent and new care models rise, India stands at a unique crossroads. The need is clear: harness technology for tangible health benefits, ensuring that innovation enhances both efficiency and patient care.
In 2023, a report showed that 82% of patients seek more innovative treatment options, indicating that this drive for change resonates widely. With continuous progress and commitment, India’s pharmaceutical sector is on the brink of significant achievements.
For further insights, check out the Indian Pharmaceutical Alliance for more updates on industry developments.
Source link
Indian Pharma, GST Reforms, RDI Scheme, Healthcare Innovation, Global Access
